GRIFOLS | GRF - Current Liabilities


GRIFOLS reported EUR2.3B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Alcon AG USD 3.17B 163M Jun/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amadeus IT EUR 3.21B 352.5M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
Cie Automotive EUR 1.92B 8.97M Dec/2025
Demant DKK 12.42B 5B Jun/2026
Ence Energia y Celulosa EUR 426.9M 11.8M Sep/2026
Essilor EUR 12.64B 490M Jun/2026
Ferrovial EUR 5.69B 778M Jun/2026
Fresenius EUR 8.08B 986M Sep/2026
Fresenius Medical Care EUR 7.91B 727.93M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Inditex EUR 13.59B 1.13B Jun/2026
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Merck EUR 8.96B 833M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Philips EUR 7.91B 485M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
Smith & Nephew USD 2.05B 510M Jun/2026
UCB EUR 4.4B 470M Dec/2025
Viscofan EUR 457.19M 10.27M Sep/2026